Suchergebnisse - "Borchiellini, Delphine"

PubPharm (94)

1

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

enthalten in: The New England journal of medicine | 2024

von Choueiri, T. | Tomczak, P. | Park, S. | +131

2

Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Carril-Ajuria, L. | Lavaud, P. | Dalban, C. | +19

3

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma : exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

enthalten in: Journal of experimental & clinical cancer research : CR | 2024

von Montemagno, C. | Jacquel, A. | Pandiani, C. | +19

4

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

enthalten in: Journal of experimental & clinical cancer research | 2024

von Montemagno, C. | Jacquel, A. | Pandiani, C. | +19

5

Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma : Analysis of the NIVOREN GETUG-AFU 26 study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Mourey, L. | Rainho, L. | Dalban, C. | +19

6

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer : Patient Preference and Cognitive Function in ODENZA

enthalten in: European urology | 2024

von Colomba, E. | Jonas, S. | Eymard, J. | +21

7

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma : 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454

enthalten in: European urology | 2024

von Plimack, E. | Powles, T. | Stus, V. | +18

ErratumFor: Eur Urol. 2023 Nov;84(5):449-454. - PMID 37500340

8

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations : cohort 2 of the randomized phase III THOR trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Siefker-Radtke, A. | Matsubara, N. | Park, S. | +113

9

Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN

enthalten in: Clinical genitourinary cancer | 2023

von Guilhem-Ducléon, G. | Dalban, C. | Negrier, S. | +13

10

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma : 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)

enthalten in: European urology | 2023

von Plimack, E. | Powles, T. | Stus, V. | +18

ErratumFor: Eur Urol. 2023 Nov;84(5):449-454. - PMID 37500340

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]